tbuckley/cabot-search huggingface dataset:
P1.03-029 A Useful Algorithmatic Model in Predicting the Likelihood of Lung Cancer in Solitary Pulmonary Nodules
Authors: Lin Gen, Zhuang Wu, Rao Ying, Zhu Shou, Zheng Feng, Chen Hui, Li Cheng, Chen Ping, Xu Wei, Wu Biao, Xu Wu, Huang Jian, Zhang Jin, Huang Cheng
Journal: Journal of Thoracic Oncology (2017)
P2.03b-043 Peripheral Blood CD45RA+ CCR7+ Naive T Cells Were Correlated with Prognosis in Non-Small Cell Lung Cancer Patients
Authors: Shu-Mei Huang, Si-Pei Wu, Ri-Qiang Liao, Zhong-Yi Dong, Hai-Yan Tu, Zhi Xie, Jian Su, Jin-Ji Yang, Xu-Chao Zhang, Yi Long Wu
Journal: Journal of Thoracic Oncology (2017)
Lower Levels of Survivin in Patients with Leukemic Low Grade B-Cell Lymphomas Expressing LMP1 Oncoprotein of Epstein-Barr Virus
Authors: Panagiotis Theodorou Diamantopoulos, Katerina Polonyphi, Maria Sofotasioiu, Athanassios Galanopoulos, Nikolaos Spanakis, George Rassidakis, Panagiotis Kouzis, Vassiliki Papadopoulou, Fani Kalala, Theodoros Iliakis, Theodoros Vassilakopoulos, Maria K. Angelopoulou, Marina Siakantaris, Evangelos Terpos, Eleni Variami, Panagoula Kollia, Gerassimos A Pangalis, Nora-Athina Viniou
Journal: Blood (2012)
S86 Understanding the role of GCN2 in modulating BMP signaling using drosophila – implications for pulmonary hypertension
Authors: E Malzer, CS Dominicus, SJ Marciniak
Journal: Thorax (2016)

<h3>Introduction and objectives</h3> The majority of inherited cases of pulmonary arterial hypertension (PAH) are caused by mutations that affect the Bone Morphogenetic Protein (BMP) receptor 2. Recently, patients with pulmonary veno-occlusive disease (PVOD), a rare subtype of pulmonary hypertension, were found to have mutations of <i>EIF2AK4</i>. This gene encodes the kinase GCN2, which regulates cellular responses to amino acid availability by phosphorylating the translation initiation factor eIF2a. Phosphorylation of eIF2a reduces protein synthesis and induces expression of a transcription factor called ATF4. It is unclear if BMP and GCN2 signalling are functionally related and so we set out to test this using the model organism <i>Drosophila melanogaster</i>. <h3>Methods</h3> We examined the development of wing veins in <i>Drosophila </i>because this is known to depend on BMP signalling. We manipulated the expression of dGCN2 and its antagonistic phosphatase dPPP1R15 by RNA interference. Morphology of the wing veins was examined in adult flies and early developmental signalling was measured in pupating animals. Similar experiments performed in animals with defective BMP signalling tested for a genetic interaction between eIF2a phosphorylation and BMP signalling. <h3>Results</h3> We observed that depletion of dGCN2 in the developing wing by RNA interference enhanced BMP signalling as evidenced by hyperphosphorylation of MAD, the <i>Drosophila</i> orthologue of SMAD1. This was associated with development of ectopic wing veins in the regions of RNAi expression. In contrast, knock down of the eIF2a phosphatase dPPP1R15 selectively impaired anterior crossvein formation. The effects of dPPP1R15 depletion were cell-autonomous suggesting an effect on downstream BMP signalling rather than on ligand secretion. The vein phenotypes were highly sensitive to manipulation of BMP signalling. Both in insect and mammalian cells, ATF4 expression inhibited BMP signalling suggesting a mechanism for the crosstalk between BMP and GCN2. <h3>Conclusion</h3> We have discovered in <i>Drosophila</i> that GCN2 activation modulates BMP signalling. This effect is mediated, at least in part, by the downstream transcription factor ATF4, which inhibits the phosphorylation of MAD (insect SMAD1). Our findings indicate that this pathway is conserved between insects and mammals and this model may shed light on the pathogenesis of PAH and PVOD.
S25 Survey of the new driver and vehicle licensing authority (DVLA) guidance for obstructive sleep apnoea (OSA): uk sleep centres opinion
Authors: EL Palmer, S West
Journal: Thorax (2016)

<h3>Introduction and objectives</h3> The DVLA produced new guidelines ‘Assessing Fitness to Drive – a guide for medical professionals’ in March 2016. An online survey was designed to seek opinion about the guidance relating to patients with OSA, which was completed in May 2016. <h3>Methods</h3> An anonymous online survey was designed and the survey link emailed to staff at UK sleep centres, identified from addresses held by the ARTP, BSS and SATA. It could be completed by any member of the sleep team, or more than one member. Responses were collated centrally. <h3>Results</h3> There were 204 survey respondents, representing sleep centres of different sizes (&lt;500 CPAP users to &gt;10,000). They included physiologists, consultants and nurses. 77% were aware the DVLA had produced new guidelines. Only 2% stated they had received communication from the DVLA about the changes. 75% did not find the new guidance for OSA easy to follow. 62% of responders said the guidelines will cause confusion for patients and potentially stop them coming forward for treatment. 33% were unclear what advice to give to their patients. The majority defined ‘excessive sleepiness’ based on symptoms (80%), including Epworth Sleepiness Score (ESS) &gt;9 (28%) or &gt;12 (56%). Only 19 people (10%) felt that apnoea-hypopnea index (AHI) &gt;5 or oxygen desaturation index (ODI) &gt;5 contributed to their assessment of patients’ sleepiness. 87% did not think AHI or ODI was a good way to assess a patient’s ability to drive. 72% of responders said the suggested frequency of follow-up appointments would increase their workload. 41% said their service did not have sufficient capacity to meet guidance for confirming adherence to treatment in group 2 drivers. 45% said their service could not meet the guidelines for reviewing symptoms and treatment compliance in patients with moderate/severe OSA with excessive sleepiness. <h3>Conclusions</h3> The new DVLA guidelines for OSA are difficult to follow for the majority of sleep professionals. These guidelines may prevent patients coming forward for assessment and treatment and will stretch the capacity of many already overworked sleep services. The guidelines require urgent further review by the DVLA and discussion with sleep experts in the UK.
Role of Genetic Polymorphisms on Response to R-Chopregimen in Diffuse Large B-Cell Lymphoma Patients: An Interim Analysis of a Multicenter Prospective Pharmacogenetic Study
Authors: Luigi Rigacci, Gabriele Perrone, Stefania Nobili, Sofia Kovalchuk, Benedetta Puccini, Federica Lancia, Renato Tassi, Marco Brugia, Ida Landini, Lara Mannelli, Gemma Benelli, Cristina Napoli, Emanuele Cencini, Alberto Fabbri, Lorenzo Iovino, Mario Petrini, Silvia Birtolo, Alessandro Melosi, Varesco Martini, Simone Santini, Carla Breschi, Paolo Bernardeschi, Carmelo Bengala, Alberto Bosi, Enrico Mini
Journal: Blood (2015)
Adult Dual Umbilical Cord Blood Transplantation Using Myeloablative Total Body Irradiation (1350cGy) and Fludarabine Conditioning
Authors: Junya Kanda, David A. Rizzieri, Cristina Gasparetto, Gwynn D. Long, John P. Chute, Keith M. Sullivan, Ashley Morris, Clayton A. Smith, Donna E. Hogge, Janet Nitta, Kevin Song, Donna Niedzwiecki, Nelson J. Chao, Mitchell E. Horwitz
Journal: Blood (2010)
TET2 mutations in Diffuse Large B-Cell Lymphoma: The Role of TET2 in the Regulation of Methylation Patterns at TET2 Target Genes
Authors: Fazila Asmar, Jesper Christensen, Jens V Johansen, Anders Blåbjerg, Anja Pedersen, Christoffer Hother, Ulrik Ralfkiaer, Kristian Helin, Kirsten Grønbæk
Journal: Blood (2011)
Determination of the Percentage of CML Patients that Achieve Continuous Complete Molecular Response Under Treatment with TKIs and Are Eligible for Participation in a TKI Discontinuation Study
Authors: George Georgiou, Maria Roumelioti, Maria Dimou, Danai Palaiologou, Angeliki Stefanou, Efstathia Staikou, Marie-Christine Kyrtsonis, Maria K. Angelopoulou, Theodoros P. Vassilakopoulos, Zacharoula I Galani, Eleni Plata, Eleni Variami, Ioannis Korantzis, Konstantinos Tsatalas, Maria Protopapa, Maria Papaioannou, Gerasimos Pangalis, Theodore Marinakis, Georgios Xanthopoulidis, Vassiliki Pappi, Elissavet Vervesou, Argiris Symeonidis, Charis Matsouka, Konstantinos Anargyrou, Konstantinos Tsionos, Nora Vyniou, Dimitra Gougopoulou, Dimitra Liapi, Dionysis Kolokythopoulos, Paraskevi Roussou, Konstantina Reppa, Eleni Poumbouridou, Eirini Katodritou, Ioannis Klonizakis, Panayiotis Panayiotidis
Journal: Blood (2011)
Asthma Is Associated with Acute Chest Syndrome, but Not an Increase Rate of Hospitalization for Pain among Children with Sickle Cell Anemia: A Retrospective Cohort Study.
Authors: Francoise Bernaudin, Robert C. Strunk, Annie Kamdem, Cecile Arnaud, Ping An, Martine Torres, Christophe Delacourt, Michael R. DeBaun
Journal: Blood (2007)
T Cell Replete HLA- Haploidentical Donor Transplantation (HIDT) with Post-Transplant Cyclophosphamide (pTcy) Is an Effective Salvage for Patients Relapsing after a Matched Sibling or a Matched Unrelated Donor Transplantation
Authors: Melhem Solh, Katelin Connor, Xu Zhang, Stacey Brown, Lawrence E. Morris, H. Kent Holland, Asad Bashey, Scott R. Solomon
Journal: Blood (2015)
Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma
Authors: Kathryn E. Beckermann, Pradeep C. Jolly, Ju Y. Kim, Jennifer Bordeaux, Igor Puzanov, W. Kimryn Rathmell, Douglas B. Johnson
Journal: Journal for ImmunoTherapy of Cancer (2017)

<h3>Background</h3> Renal medullary carcinoma (RMC) is a rare kidney tumor that occurs in adolescent and young adults, typically in association with sickle cell trait. RMC exhibits rapid disease progression, frequent metastases at diagnosis, and dismal clinical outcomes. Currently available therapies, including cisplatin-based combination chemotherapy, multi-tyrosine kinase, and mTOR inhibitor strategies demonstrate either transient responses or minimal activity. Therefore, further molecular characterization and additional treatment strategies are urgently needed in this aggressive disease. The role of immune system surveillance and responsiveness to anti-PD-1 therapies in RMC are completely unexplored. <h3>Case presentation</h3> A 29&nbsp;year old male with sickle cell trait presented with painless hematuria that ultimately resulted in a diagnosis of RMC. He underwent total nephrectomy and adjuvant cytotoxic chemotherapy with carboplatin, gemcitabine, paclitaxel, and bevacizumab. As is common in this aggressive form of kidney cancer he recurred with biopsy proven lymph node metastasis. He was started on checkpoint inhibitor therapy with nivolumab that inhibits program cell death protein 1 (PD-1), and on his first follow-up imaging he was found to have a partial response that on subsequent scans ultimately resulted in a complete response lasting greater than nine months. In this report, we present a patient with metastatic RMC who exhibited a clinical response to nivolumab, as well as the genetic and immunologic correlates of the pre-treatment tumor. Provocatively, robust immune infiltrate and expression of immune checkpoints were observed, despite the presence of a low mutation burden. <h3>Conclusions</h3> Here, we report the first case of immune microenvironment profiling and response to anti-PD-1 in a patient with RMC to our knowledge. This case suggests that anti-PD-1 based therapies may have clinical activity in RMC.
T2 Early-life respiratory tract infection and adult susceptibility to chronic mucus hypersecretion – a prospective 64 year national birth cohort study
Authors: JP Allinson, R Hardy, GC Donaldson, SO Shaheen, D Kuh, JA Wedzicha
Journal: Thorax (2016)

<h3>Introduction</h3> Smoking commonly triggers Chronic Mucus Hypersecretion (CMH) indicating both accelerated FEV<sub>1</sub> decline and arguably early-phase COPD development. Early-life respiratory infections are proposed as another cause of adult CMH and also lead to impaired adult lung function. We investigated how smoking may modify the relationship between early-life infection and CMH across adult life. <h3>Methods</h3> The MRC National Survey of Health and Development has prospectively studied a nationally representative sample of men and women since their birth during one week in March 1946 within England, Scotland and Wales. During early-life (ages 0 to 2 years) lower respiratory tract infection presence (EL-LRTI), father's occupational social class and estimated local pollution exposure were recorded for each study member. Smoking status and MRC questionnaire defined CMH were recorded six times between age 20 and 60–64 years. Random-effects logistic regression models for repeated measures were used to describe CMH trajectories across adult life by smoking status and EL-LRTI adjusting for sex, birth weight, early-life pollution exposure (high vs low) and social class (manual vs non-manual). <h3>Results</h3> Amongst the 3617 individuals included (52% male; 63% ever-smokers) 25% experienced an EL-LRTI. CMH prevalence increased during adulthood (cumulative prevalence = 12%). Smokers had higher odds of CMH at all ages compared to non-smokers (Figure 1). For smokers and non-smokers, those with EL-LRTI had higher odds of CMH than those without EL-LRTI. There was evidence of an interaction between smoking status and EL-LRTI (Figure 1) such that at age 20 the effect of EL-LRTI (EL-LRTI+ve versus EL-LRTI–ve) was greater in non-smokers (OR = 4.0 (95% confidence interval (CI): 1.9 to 8.2; P &lt; 0.001) than in smokers (OR = 1.48 CI: 0.8 to 2.6; P = 0.17). In non-smokers only the association between EL-LRTI and adult CMH lessened with ageing. Thus by age 60, the effect of EL-LRTI on the odds of having CMH (EL-LRTI+ve versus EL-LRTI–ve) amongst non-smokers (OR = 1.4 (CI: 0.8 to 2.4; P = 0.21)) and smokers (OR = 1.6 CI: 0.8 to 3.1; P = 0.15) was similar. <h3>Conclusion</h3> Infants with respiratory infections become adults predisposed to developing CMH potentially reflecting pulmonary damage sustained during early-life or an overarching altered susceptibility to respiratory insults. This relationship is modulated by smoking and ageing.
P67 Is there a difference between the sleep physiology of obese and super obese patients?
Authors: A Rajhan, L Michael, A Bain, A Thomas, M Allen
Journal: Thorax (2016)

<h3>Introduction</h3> Bariatric surgery is increasingly recommended for managing patients who are both obese and super obese (BMI ≥45 ref. WHO Classification). We have compared if there are physiological and subjective differences between patients in these two categories. <h3>Methods</h3> Patients assessed for bariatric surgery were split into the super obese and obese group. Their physiological parameters including Apnoea Hypopnoea Index(AHI), Desaturation Index(ODI &gt;4%) and subjective results i.e., Epworth Sleepiness Score(ESS) and STOPBANG Questionnaire were compared. <h3>Results</h3> 111 patients assessed for bariatric surgery attended for limited sleep studies from a period between July 2013 to December 2014. 57 patients were obese (40 females) and 54 were superobese (37 females) and the results are tabulated below. (Table 1) The superobese patients had a higher AHI, ODI and time spent desaturated when compared to the obese patients. <h3>Conclusion</h3> 1) There is more physiological derangement in the super obese patient group so greater caution is needed in the administration of anaesthetic to such patients. 2) Despite the physiological derangement, superobese patients were less sleepy based on their ESS, the reasons for which are not entirely clear.
P3.01-016 Factors Influencing the Concordance of Histological Subtype Diagnosis by Biopsy and Resected Specimens of Lung Adenocarcinoma
Authors: Reiko Matsuzawa, Keisuke Kirita, Shigeki Umemura, Shingo Matsumoto, Kiyotaka Yoh, Seiji Niho, Masahiro Tsuboi, Koichi Goto, Genichiro Ishii
Journal: Journal of Thoracic Oncology (2017)
Refractory subacute steatohepatitis after biliopancreatic diversion
Authors: Sander Lefere, Anne Hoorens, Sarah Raevens, Roberto Troisi, Xavier Verhelst, Hans Van Vlierberghe, Anja Geerts
Journal: Hepatology (2017)

Lefere, Sander*,1; Hoorens, Anne2; Raevens, Sarah1; Troisi, Roberto3; Verhelst, Xavier1; Van Vlierberghe, Hans1; Geerts, Anja*,1 Author Information
Socioeconomic and ethnic inequities within organised colorectal cancer screening programmes worldwide
Authors: CM de Klerk, S Gupta, E Dekker, ML Essink-Bot
Journal: Gut (2017)

<h3>Objective</h3> Colorectal cancer (CRC) screening programmes can reduce CRC mortality. However, the implementation of a screening programme may create or exacerbate socioeconomic and ethnic health inequities if participation varies by subgroup. We determined which organised programmes characterise participation inequities by socioeconomic and ethnic subgroups, and assessed the variation in subgroup participation among programmes collecting group-specific data. <h3>Design</h3> Employing a literature review and survey among leaders of national or regional screening programmes, this study identified published and unpublished data on participation by socioeconomic status and ethnicity. We assessed programmes offering faecal occult blood tests (FOBT) for screening. Primary outcome was screening participation rate. <h3>Results</h3> Across 24 organised FOBT-screening programmes meeting the inclusion criteria, participation rates ranged from 21% to 73%. Most programmes (13/24, 54%) did not collect data on participation by socioeconomic status and ethnicity. Among the 11 programmes with data on participation by socioeconomic status, 90% (28/31 publications) reported lower participation among lower socioeconomic groups. Differences across socioeconomic gradients were moderate (66% vs 71%) to severe (35% vs 61%). Only six programmes reported participation results by ethnicity. Ethnic differences were moderate, though only limited data were available for evaluation. <h3>Conclusions</h3> Across organised CRC screening programmes worldwide, variation in participation by socioeconomic status and ethnicity is often not assessed. However, when measured, marked disparities in participation by socioeconomic status have been observed. Limited data were available to assess inequities by ethnicity. To avoid exacerbating health inequities, screening programmes should systematically monitor participation by socioeconomic status and ethnicity, and investigate and address determinants of low participation.
Complete Responses in Patients with Autoimmune Lymphoproliferative Syndrome (ALPS) Using the mTOR Inhibitor Sirolimus (rapamycin)
Authors: Davi d T. Teachey, Robert J Greiner, Dirk Schwabe, Jack Bleesing, Catherine Scott Manno, Kathleen Sullivan, Daniel S. Wechsler, Stephan A. Grupp
Journal: Blood (2008)
Time to tumor progession (TTP) of patients with octreotide-positive metastatic low-grade well-differentiated gastrointestinal neuroendocrine tumors (GEPNETs).
Authors: K. G. Do, E. Wyluda, M. Capanu, L. H. Tang, D. L. Reidy
Journal: Journal of Clinical Oncology (2011)

e14516 Background: Defining prognosis in our patients with metastatic well-differentiated NETs poses a significant challenge because of tumor heterogeneity and varying degree of aggressiveness. Somatostatin scintigraphy (herein Octreoscan) positive disease and histologic grade (defined by Ki-67 or mitotic rate) are 2 predictors that could be used to determine prognosis. We sought to measure TTP of newly diagnosed well differentiated low grade Octreoscan positive GEPNETs at the time of diagnosis with liver metastases. Methods: Computerized medical records identified patients who underwent an Octreoscan SPECT-CT (2007-2010). Octreoscans and CT or MRI were reviewed by a radiologist at the time of diagnosis. TTP was defined by RECIST version 1.1. Pathology slides (11 metastatic sites,1 terminal ileum) were reviewed by a pathologist. Well differentiated intermediate grade and high grade NEC were excluded. Clinical records were reviewed as indicated. Patients without liver metastases, with insufficient follow-up, who underwent surgery or embolization prior to disease progression, or had insufficient pathology were excluded. All enrolled patients were started on octreotide therapy alone at the time of diagnosis. Results: Twelve eligible patients were identified: 8 pNET, 4 small bowel. With a median follow-up of approximately 3 years, median TTP was 16.8 months with 95% CI 5.9 to infinity. The wide TTP range was irrespective of organ of origin or clinical features (i.e. tumor burden, functional tumor). Four patients had a TTP < 6 months and 2/4 died within 3 years of their diagnosis. 5/12 had a TTP ≥ 1 year, 1 of which died 5 years after diagnosis. 3/12 patients have not yet reached TTP. Conclusions: Generally, low grade well differentiated octreotide positive NETs follow an indolent course, however, clinical behavior can be heterogeneous irrespective of treatment. Undersampling of the tumor may be one reason to explain the discrepancy. Reliable genomic clinical or other radiographic predictors could provide significant advancements in prognosis and, possibly, treatment.
Squamous Cell Carcinoma and Other Lesions of the Fore-Stomach in Mice, Following Oral Administration of 20-Methylcholanthrene and 1,2,5,6-Dibenzanthracene (Preliminary Report)
Authors: Egon Lorenz, Harold L. Stewart
Journal: JNCI Journal of the National Cancer Institute (1940)

Journal Article Squamous Cell Carcinoma and Other Lesions of the Fore-Stomach in Mice, Following Oral Administration of 20-Methylcholanthrene and 1,2,5,6-Dibenzanthracene (Preliminary Report) Get access Egon Lorenz, Egon Lorenz senior biophysicist National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar Harold L. Stewart Harold L. Stewart senior pathologist National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 1, Issue 2, October 1940, Pages 273–276, https://doi.org/10.1093/jnci/1.2.273 Published: 01 October 1940